CorMedix Inc.

Stock factsheet

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

CorMedix is a biopharmaceutical company specialising in the prevention and treatment of catheter-related infections. Its lead product DefenCath is an antimicrobial catheter lock solution that has received FDA approval for use in haemodialysis patients. The company markets DefenCath to dialysis centres in the United States.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

Investor Relations

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.